Ugo Johnson Agwu, in District Hts, MD - Social Worker

Ugo Johnson Agwu, is a Social Worker - Clinical based in District Hts, Maryland. Ugo Johnson Agwu is licensed to practice in District Of Columbia (license number LC500181850) and her current practice location is 6571 Hil Mar Dr Apt 301, District Hts, Maryland. She can be reached at her office (for appointments etc.) via phone at (202) 422-9792.

NPI number for Ugo Johnson Agwu is 1548734312 and her current mailing address is 6571 Hil Mar Dr Apt 301, District Hts, Maryland. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1548734312.

Contact Information

	Ugo Johnson Agwu,
	6571 Hil Mar Dr Apt 301, District Hts, MD 20747-4136
	(202) 422-9792
	Not Available

Healthcare Provider's Profile

Full Name	Ugo Johnson Agwu
Gender	Female
Speciality	Social Worker - Clinical
Location	6571 Hil Mar Dr Apt 301, District Hts, Maryland
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1548734312
Provider Enumeration Date: 01/15/2019
Last Update Date: 01/15/2019

Medical Identifiers

Medical identifiers for Ugo Johnson Agwu such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1548734312	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
1041C0700X	Social Worker - Clinical	LC500181850 (District Of Columbia)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Ugo Johnson Agwu is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Ugo Johnson Agwu, 6571 Hil Mar Dr Apt 301, District Hts, MD 20747-4136 Ph: (202) 422-9792	Ugo Johnson Agwu, 6571 Hil Mar Dr Apt 301, District Hts, MD 20747-4136 Ph: (202) 422-9792

News Archive

CFFT, Vertex collaborate to develop new medicines for cystic fibrosis

Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics, Inc. today announced they will collaborate on the continued discovery and development of new medicines known as correctors that aim to treat the underlying cause of cystic fibrosis in people with the most common form of the disease.

ManagementPlus EHR 5.0 achieves pre-market, eRX conditional CCHIT Certified 2011 status

Healthcare and opthalmology practices can manage Electronic Health Records with confidence and ease, thanks to practice management solution provider ManagementPlus. A pioneer in advanced EHR solutions, ManagementPlus continues to uphold its leadership position with today's announcement that the company's flagship product, ManagementPlus EHR 5.0, is a pre-market and ePrescribing conditionally CCHIT Certified 2011 Ambulatory EHR.

Health-care reform bills continue to benefit illegal aliens

Assurances that the two health-care reform bills would not benefit illegal aliens are not accurate. A new report from the Center for Immigration Studies examines in detail the immigration-related provisions of both the House-passed HR 3962 and the bill now being debated in the Senate, HR 3590. The report concludes that the bills, in their current form, would indeed give illegal aliens access to taxpayer-funded health care well beyond emergency medical treatment.

Adamas Pharmaceuticals forges agreement with U.S. Naval Health Research Center for evaluating triple combination antiviral drug

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Naval Health Research Center for preclinical studies evaluating Adamas' triple combination antiviral drug (TCAD) therapy for influenza A, including novel influenza A/H1N1. TCAD therapy includes Adamas' investigational proprietary fixed-dose oral combination drug, to be administered adjunctively with a neuraminidase inhibitor, including Tamiflu (oseltamivir phosphate, Roche).

Ugo Johnson Agwu, - Clinical Social Worker in District Hts, MD